Cancer Therapy News and Research

RSS

Exelixis announces cabozantinib preclinical data on pancreatic cancer

Exelixis, Inc. today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and VEGF signaling reduces tumor invasiveness and metastasis in preclinical models of pancreatic cancer.

26 Feb 2012

Scientists identify specific pathways behind breast cell's transformation into cancer

Although it's widely accepted that inflammation is a critical underlying factor in a range of diseases, including the progression of cancer, little is known about its role when normal cells become tumor cells. Now, scientists from the Florida campus of The Scripps Research Institute have shed new light on exactly how the activation of a pair of inflammatory signaling pathways leads to the transformation of normal breast cells to cancer cells.

24 Feb 2012

Women over 40 have better prognosis after mammography screening

Based on a study of nearly 2,000 breast cancer patients, researchers at the Swedish Cancer Institute in Seattle say that, in women between the ages of 40 and 49, breast cancers detected by mammography have a better prognosis. The study appears in the March issue of Radiology.

23 Feb 2012

Accelitech announces new CyberKnife Cancer Institute of Chicago

Accelitech LLC, a leading developer of stereotactic radiosurgery and cancer treatment programs, is pleased to announce its newest CyberKnife cancer center, which will begin treating patients in Chicago in the summer of 2012.

23 Feb 2012

Insight into relationship between two types of suppressors in cancerous tumors

The University of Kentucky has announced that Dr. Daret St. Clair, the James Graham Brown Endowed Chair and professor of toxicology, has published the first comprehensive study that provides insight into the relationship between two types of suppressors in cancerous tumors. The results will enhance the understanding of transcriptional mechanisms in carcinogenesis.

23 Feb 2012

Accelitech embarks on a proton cancer therapy project

Accelitech LLC, the leader in the development and full-cycle management of technology-driven cancer treatment programs, is pleased to announce its inaugural proton therapy project. The treatment center project, now under development, is the latest in Accelitech's ongoing effort to bring leading treatment technologies to more patients through joint-venture partnerships with physicians and hospitals.

23 Feb 2012

FDA approves APP's preservative-free Methotrexate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.

22 Feb 2012

Mitochondria may be promising new target for cancer treatment

Mitochondria, tiny structures within each cell that regulate metabolism and energy use, may be a promising new target for cancer therapy, according to a new study. Manipulation of two biochemical signals that regulate the numbers of mitochondria in cells could shrink human lung cancers transplanted into mice, a team of Chicago researchers report in the journal FASEB.

22 Feb 2012

Weight gain or loss may also depend on medicines taken

Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking.

22 Feb 2012

Charité launches new EU research project to personalize breast cancer treatment

Adjusting breast cancer therapy to individual patients to avoid ineffective treatment: Charité Universitätsmedizin Berlin and eleven partner institutions from six countries have set this as their goal. They have launched the EU research project RESPONSIFY.

20 Feb 2012

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Blocking autophagy -- the process of "self-eating" within cells -- is turning out to be a viable way to enhance the effectiveness of a wide variety of cancer treatments.

19 Feb 2012

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.

18 Feb 2012

LUMC named one of the nation's top hospitals in cancer treatment

Loyola University Medical Center has been named one of the nation's top hospitals in cancer research, prevention, treatment and education by Becker's Hospital Review.

17 Feb 2012

Four new drugs can extend survival and prognosis of prostate cancer

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says.

17 Feb 2012

Nordion celebrates first anniversary of market launch of TheraSphere

Nordion Inc., a leading provider of products and services to the global health science market, today celebrated the first anniversary of the market introduction of TheraSphere, an innovative radioembolic liver cancer therapy, in the Republic of Turkey.

17 Feb 2012

Biochemists determine first crystal structure of an immunoproteasome

Like a shredder, the immunoproteasome cuts down proteins into peptides that are subsequently presented on the cellular surface. The immune system can distinguish between self and nonself peptides and selectively kills cells that due to a viral infection present non-self peptides at their surface. In autoimmune diseases this mechanism is deregulated and the immune system also eliminates uninfected cells by mistake.

16 Feb 2012

Combination of photodynamic therapy and software can treat internal tumours

Laser light in combination with certain drugs - known as photodynamic therapy - can destroy cancer tumours, but is today used mostly to cure skin cancer. The reason that internal tumours are not treated with the method is that the technology does not exist to check that the precise amount of light is administered. However, software developed by researchers in atomic physics at Lund University in Sweden looks like being able to solve the problem.

16 Feb 2012

Cancer cell communication signals may contain pieces of RNA

Researchers have shown that the communication signals sent around the body by cancer cells, which are essential for the cancer to grow, may contain pieces of RNA - these substances, like DNA, are pieces of genetic code that can instruct cells, and ultimately the body, how to form. The same study also found early indications that these genetic instructions can be intercepted and modified by chemotherapy to help prevent cancer cells growing.

16 Feb 2012

Diffusion-weighted MRI may effectively indicate response to ovarian cancer treatment

Cancer Research UK-funded scientists have determined that a magnetic resonance imaging (MRI) technique, which measures the movement of water molecules within the tumour, may be the best way to monitor how women with late-stage ovarian cancer are responding to treatment. The study is published in the journal Radiology today.

14 Feb 2012

Epigenetic mechanisms maintain tolerance in T cells specific for self antigens

At the most basic level, the immune system must distinguish self from non-self, that is, it must discriminate between the molecular signatures of invading pathogens (non-self antigens) and cellular constituents that usually pose no risk to health (self-antigens).

14 Feb 2012